Allergan (AGN) Set to Announce Quarterly Earnings on Tuesday
Allergan (NYSE:AGN) is scheduled to be issuing its quarterly earnings data on Tuesday, October 29th. Allergan has set its Q3 guidance at $1.18-1.20 EPS and its FY13 guidance at $4.72-4.76 EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.
Allergan (NYSE:AGN) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter last year, the company posted $1.07 earnings per share. Allergan’s revenue was up 10.2% compared to the same quarter last year. On average, analysts expect Allergan to post $4.76 EPS for the current fiscal year and $5.40 EPS for the next fiscal year.
Allergan (NYSE:AGN) opened at 92.82 on Monday. Allergan has a 52 week low of $81.33 and a 52 week high of $116.45. The stock’s 50-day moving average is $89.87 and its 200-day moving average is $99.37. The company has a market cap of $27.554 billion and a price-to-earnings ratio of 29.85.
AGN has been the subject of a number of recent research reports. Analysts at JMP Securities reiterated an “outperform” rating on shares of Allergan in a research note to investors on Thursday, October 17th. On the ratings front, analysts at Credit Suisse initiated coverage on shares of Allergan in a research note to investors on Tuesday, October 8th. They set an “outperform” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Allergan in a research note to investors on Monday, September 16th. They now have a $93.00 price target on the stock. Eleven equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $107.00.
In other Allergan news, Director Trevor Jones sold 2,000 shares of Allergan stock on the open market in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $90.14, for a total transaction of $180,280.00. Following the transaction, the director now directly owns 7,142 shares of the company’s stock, valued at approximately $643,780. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Allergan, Inc, is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.